Chief says J&J is on road to recovery
The US pharmaceuticals group looks ahead to the relaunch of consumer products that were withdrawn after a series of damaging recalls last year
Source: FT.com - Pharmaceuticals
J&J to link up product marketing
The move to market consumer health products packaged with prescription medicines aims to strengthen links among parts of the group's business
Source: FT.com - Pharmaceuticals
Johnson & Johnson Fined
Health care manufacturer Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil investigations over allegations that they marketed three drugs for uses that were never approved, and that kickbacks were paid to physicians and to a long-term care pharmacy provider, U.S. Attorney General Eric Holder said today in Washington.
The drugs involved are Risperdal, Invega and Natrecor. Ref. CNN
California judge throws out $417 million award against Johnson & Johnson in claim baby powder caused cancer. Eva Echeverria alleged Johnson & Johnson failed to adequately warn consumers about talcum powder's potential cancer risks. Los Angeles County Superior Court Judge Maren Nelson granted the company's request for a new trial. He also ruled that there wasn't convincing evidence that Johnson & Johnson acted with malice and the award for damages was excessive. Similar allegations have led to hundreds of lawsuits against the New Jersey-based company and jury awards have totaled hundreds of millions of dollars. Ref. USAToday.
Johnson & Johnson to pay $572 million for fueling Oklahoma's opioid-addiction crisis, judge rules. An Oklahoma judge on Monday found Johnson & Johnson and its subsidiaries helped fuel the state’s opioid drug crisis and ordered the consumer products giant to pay $572 million to help abate the problem in the coming years. The companies are expected to appeal the ruling to the Oklahoma Supreme Court. Ref. USAToday.
FDA authorizes Johnson & Johnson's one-dose COVID vaccine, doses expected to start rolling next week. The U.S. Food and Drug Administration, as expected, has authorized a third COVID-19 vaccine for public use. About 4 million doses of the new vaccine should be made available next week, 20 million total during March, and another 80 million by the end of June. Ref. USAToday.